AstraZeneca ADR


SKU: AZN-1 Category:


AstraZeneca PLC delivered a mixed result in the recent quarter, with revenues below market expectations, but managed to surpass the analyst consensus regarding earnings. They reported a 5% increase in total revenue, reaching $33.8 billion in the first nine months of the year. Notably, the non-COVID-19 medicines demonstrated a robust 15% growth, offsetting the $2.9 billion decline in revenue from COVID-19 medicines. Core earnings per share surged by 17%, reaching $5.80. The diverse commercial portfolio and global footprint proved instrumental in this success, prompting an upgrade in the 2023 guidance, anticipating low teen percentage growth in total revenue excluding COVID and a similar increase in core EPS. Emerging markets, excluding China, experienced an impressive 37% year-to-date growth, reinforcing confidence in their future significance. AstraZeneca’s strategic advantage lies in its limited exposure to patent expiries, boasting a diverse portfolio and an industry-leading late-stage pipeline. With a focus on sustainable long-term growth, the company is investing in revolutionary modalities like ADCs, aiming to replace traditional chemotherapy. The company further agreed to acquire Icosavax to enhance its proficiency in respiratory syncytial virus, bolstering AstraZeneca’s late-stage pipeline for Vaccines & Immune Therapies with Icosavax’s primary experimental vaccine candidate, IVX-A12.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!